Cellectar Biosciences‘ Phospholipid Drug Conjugate (PDC) research program has generated numerous PDC molecules that show “significant” improved pharmacologic activity, the company announced today.

According to a release, Cellectar’s research demonstrates that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells.

“The rapid advancement and positive data from these research programs, coupled with our ongoing collaborations, further validate the unique capabilities and broad utility of our PDC platform,” Cellectar Biosciences CEO Jim Caruso said in a statement.

Cellectar also announced it is currently developing internal PDC programs.